411 related articles for article (PubMed ID: 19041828)
1. Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer.
Pacini F; Castagna MG
Best Pract Res Clin Endocrinol Metab; 2008 Dec; 22(6):1009-21. PubMed ID: 19041828
[TBL] [Abstract][Full Text] [Related]
2. Overview on the use of recombinant human thyrotropin in thyroid cancer of follicular cell origin.
Zanotti-Fregonara P; Toubert ME; Taieb D; Ravasi L; Rubello D; Hindie E
Minerva Endocrinol; 2008 Jun; 33(2):53-65. PubMed ID: 18332849
[TBL] [Abstract][Full Text] [Related]
3. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
[TBL] [Abstract][Full Text] [Related]
4. The role of recombinant thyroid-stimulating hormone (rhTSH) in the detection and management of well-differentiated thyroid carcinoma: a roundtable discussion.
Schlumberger MJ; Incerti C; Pacini F; Reiners C
J Endocrinol Invest; 1999; 22(11 Suppl):35-41. PubMed ID: 10727004
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience.
Perros P
J Endocrinol Invest; 1999; 22(11 Suppl):30-4. PubMed ID: 10727003
[TBL] [Abstract][Full Text] [Related]
6. Uses for recombinant human TSH in patients with thyroid cancer and nodular goiter.
Woodmansee WW; Haugen BR
Clin Endocrinol (Oxf); 2004 Aug; 61(2):163-73. PubMed ID: 15272910
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
8. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy.
Molinaro E; Viola D; Passannanti P; Agate L; Lippi F; Ceccarelli C; Pinchera A; Elisei R
Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):490-502. PubMed ID: 19910902
[TBL] [Abstract][Full Text] [Related]
10. [Clinical application of recombinant human thyroid-stimulating hormone in management of differentiated thyroid carcinoma].
Liu B; Kuang A
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2012 Jun; 29(3):588-92. PubMed ID: 22826964
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human thyroid-stimulating hormone (rhTSH): clinical development.
Incerti C
J Endocrinol Invest; 1999; 22(11 Suppl):8-16. PubMed ID: 10727000
[TBL] [Abstract][Full Text] [Related]
12. Serum thyroglobulin determination in thyroid cancer patients.
Francis Z; Schlumberger M
Best Pract Res Clin Endocrinol Metab; 2008 Dec; 22(6):1039-46. PubMed ID: 19041830
[TBL] [Abstract][Full Text] [Related]
13. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.
Pötzi C; Moameni A; Karanikas G; Preitfellner J; Becherer A; Pirich C; Dudczak R
Clin Endocrinol (Oxf); 2006 Oct; 65(4):519-23. PubMed ID: 16984246
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human thyrotropin is helpful in the follow-up and 131I therapy of patients with thyroid cancer: a report of the results and benefits using recombinant human thyrotropin in clinical routine.
Kohlfuerst S; Igerc I; Lind P
Thyroid; 2005 Apr; 15(4):371-6. PubMed ID: 15876162
[TBL] [Abstract][Full Text] [Related]
15. Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer.
Torlontano M; Crocetti U; D'Aloiso L; Bonfitto N; Di Giorgio A; Modoni S; Valle G; Frusciante V; Bisceglia M; Filetti S; Schlumberger M; Trischitta V
Eur J Endocrinol; 2003 Jan; 148(1):19-24. PubMed ID: 12534353
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): serum thyroglobulin measurement.
Pacini F; Lippi F
J Endocrinol Invest; 1999; 22(11 Suppl):25-9. PubMed ID: 10727002
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels.
Pellegriti G; Scollo C; Regalbuto C; Attard M; Marozzi P; Vermiglio F; Violi MA; Cianci M; Vigneri R; Pezzino V; Squatrito S
Clin Endocrinol (Oxf); 2003 May; 58(5):556-61. PubMed ID: 12699436
[TBL] [Abstract][Full Text] [Related]
18. Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions.
Mazzaferri EL; Kloos RT
Thyroid; 2000 Sep; 10(9):767-78. PubMed ID: 11041454
[TBL] [Abstract][Full Text] [Related]
19. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
20. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
